There are currently 312 clinical trials in Norfolk, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital of the King's Daughters, Virginia Oncology Associates, Sentara Norfolk General Hospital and Eastern Virginia Medical School. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
06/19/2025
Locations: Children's Specialty Group, Norfolk, Virginia
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Register for Updates
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368
Recruiting
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
06/19/2025
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Aortic Stenosis
Register for Updates
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
NCT06341712
Recruiting
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery. Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid. Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young... Read More
Gender:
ALL
Ages:
Between 5 years and 30 years
Trial Updated:
06/19/2025
Locations: Children's Hospital of the King's Daughters, Norfolk, Virginia
Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Register for Updates
Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration
NCT04567303
Recruiting
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/19/2025
Locations: Wagner Kapoor Institute, Norfolk, Virginia
Conditions: Macular Degeneration
Register for Updates
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082
Recruiting
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Non-Small Cell Lung Cancer
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Norfolk, Virginia
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: 84000156 - Tidewater Kidney Specialists, Norfolk, Virginia
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NCT05591118
Recruiting
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Sentara Health Research Center, Norfolk, Virginia
Conditions: Pulmonary Embolism
Register for Updates
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT06450639
Recruiting
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD age ≥ 8 to \< 18 years old receiving corticosteroid therapy.
Gender:
MALE
Ages:
Between 8 years and 17 years
Trial Updated:
06/18/2025
Locations: Child's Hosp King's Daughters, Norfolk, Virginia
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
Recruiting
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2025
Locations: Children's Specialty Group - 3 Commercial Place, Norfolk, Virginia
Conditions: Episodic Migraine
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/17/2025
Locations: Children's Specialty Group, Norfolk, Virginia
Conditions: Chronic Migraine in Children
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Digestive & Liver Disease Specialists, Norfolk, Virginia
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates